We’re pleased to have released a robust set of annual results today, reflecting revenue growth of 9.8% in the 2023/24 financial year. The results were presented together with a new strategy and a new structure for the Group, focusing on two distinct business divisions: Imaging & Analysis and Advanced Technologies. Richard Tyson, CEO of Oxford Instruments plc, said: “I am pleased with the results for the full year and the development of the business during the year. We have reported strong revenue growth of 9.8% at constant currency, with adjusted operating profit in line with expectations. I am grateful to my colleagues across Oxford Instruments for their commitment and energy through a busy year." For more, please read our full results announcement: https://lnkd.in/e2gHkYuZ. #results #strategy
Oxford Instruments plc’s Post
More Relevant Posts
-
Connecticut ranks among the top 10 states for research and development spending, according to a new U.S. Bureau of Economic Analysis report. That number represents more than $7.9 billion in spending, an increase of 22% over the previous year and up 44% since 2017.
“Lawmakers must continue implementing policies that support and promote R&D investments across all sectors,” CBIA’s Chris DiPentima tells the The Hartford Courant about a new Bureau of Economic Analysis report that shows Connecticut ranks among the top 10 states for research and development spending. DiPentima notes that R&D is crucial to driving innovation, particularly in the aerospace and bioscience sectors. #researchanddevelopment #innovation #cteconomy #aerospace #manufacturing #bioscience #Connecticut
-
Paul Drechsler's article in The Times emphasises the need for a unified industrial strategy in the UK. This country holds incredible potential in sectors like health, bioscience, biotech, fintech, arts, culture, and universities. Imagine the impact if we fully leveraged these strengths! Read the full article to learn more: https://lnkd.in/egFbyV4c #UKIndustry #Collaboration #Innovation #EconomicGrowth #IndustrialStrategy
Britain has never needed an industrial strategy more than today
thetimes.co.uk
-
M&A activity in life sciences (LS) held steady in Q3’23 despite concerns over the economy and political unrest. But as recession fears ease and interest rates level out, M&A activity is expected to pick up in 2024. Learn about M&A trends and how to take advantage of LS investment opportunities.
Q3'23 M&A trends in life sciences: Dealmaking holds steady
kpmg.voicestorm.com
-
M&A activity in life sciences (LS) held steady in Q3’23 despite concerns over the economy and political unrest. But as recession fears ease and interest rates level out, M&A activity is expected to pick up in 2024. Learn about M&A trends and how to take advantage of LS investment opportunities.
Q3'23 M&A trends in life sciences: Dealmaking holds steady
kpmg.voicestorm.com
-
Salesforce CRM(Sales,Service,B2B eCommerce, Order Mgmt.) Expert across Industries(CPG/Manufacturing). 22+yrs experience In Technology Consulting, CRM Sol Arch, Project Management, Pre Sales and Sales/Marketing.
M&A activity in life sciences (LS) held steady in Q3’23 despite concerns over the economy and political unrest. But as recession fears ease and interest rates level out, M&A activity is expected to pick up in 2024. Learn about M&A trends and how to take advantage of LS investment opportunities.
Q3'23 M&A trends in life sciences: Dealmaking holds steady
kpmg.voicestorm.com
-
M&A activity in life sciences (LS) held steady in Q3’23 despite concerns over the economy and political unrest. But as recession fears ease and interest rates level out, M&A activity is expected to pick up in 2024. Learn about M&A trends and how to take advantage of LS investment opportunities.
Q3'23 M&A trends in life sciences: Dealmaking holds steady
kpmg.voicestorm.com
-
M&A activity in life sciences (LS) held steady in Q3’23 despite concerns over the economy and political unrest. But as recession fears ease and interest rates level out, M&A activity is expected to pick up in 2024. Learn about M&A trends and how to take advantage of LS investment opportunities.
Q3'23 M&A trends in life sciences: Dealmaking holds steady
kpmg.voicestorm.com
-
M&A activity in life sciences (LS) held steady in Q3’23 despite concerns over the economy and political unrest. But as recession fears ease and interest rates level out, M&A activity is expected to pick up in 2024. Learn about M&A trends and how to take advantage of LS investment opportunities.
Q3'23 M&A trends in life sciences: Dealmaking holds steady
kpmg.voicestorm.com
-
M&A activity in life sciences (LS) held steady in Q3’23 despite concerns over the economy and political unrest. But as recession fears ease and interest rates level out, M&A activity is expected to pick up in 2024. Learn about M&A trends and how to take advantage of LS investment opportunities.
Q3'23 M&A trends in life sciences: Dealmaking holds steady
kpmg.voicestorm.com
-
M&A activity in life sciences (LS) held steady in Q3’23 despite concerns over the economy and political unrest. But as recession fears ease and interest rates level out, M&A activity is expected to pick up in 2024. Learn about M&A trends and how to take advantage of LS investment opportunities.
Q3'23 M&A trends in life sciences: Dealmaking holds steady
kpmg.voicestorm.com
